全文获取类型
收费全文 | 36417篇 |
免费 | 4199篇 |
国内免费 | 1714篇 |
专业分类
耳鼻咽喉 | 499篇 |
儿科学 | 622篇 |
妇产科学 | 649篇 |
基础医学 | 2666篇 |
口腔科学 | 688篇 |
临床医学 | 4711篇 |
内科学 | 4834篇 |
皮肤病学 | 390篇 |
神经病学 | 1698篇 |
特种医学 | 1503篇 |
外国民族医学 | 74篇 |
外科学 | 5584篇 |
综合类 | 9895篇 |
现状与发展 | 114篇 |
预防医学 | 1555篇 |
眼科学 | 738篇 |
药学 | 2331篇 |
25篇 | |
中国医学 | 768篇 |
肿瘤学 | 2986篇 |
出版年
2024年 | 40篇 |
2023年 | 978篇 |
2022年 | 1307篇 |
2021年 | 1884篇 |
2020年 | 1963篇 |
2019年 | 1018篇 |
2018年 | 1094篇 |
2017年 | 1025篇 |
2016年 | 1050篇 |
2015年 | 1488篇 |
2014年 | 2341篇 |
2013年 | 2190篇 |
2012年 | 2736篇 |
2011年 | 2791篇 |
2010年 | 2066篇 |
2009年 | 1994篇 |
2008年 | 1983篇 |
2007年 | 2650篇 |
2006年 | 2345篇 |
2005年 | 1966篇 |
2004年 | 1771篇 |
2003年 | 1301篇 |
2002年 | 1031篇 |
2001年 | 726篇 |
2000年 | 479篇 |
1999年 | 448篇 |
1998年 | 333篇 |
1997年 | 218篇 |
1996年 | 114篇 |
1995年 | 100篇 |
1994年 | 188篇 |
1993年 | 121篇 |
1992年 | 127篇 |
1991年 | 110篇 |
1990年 | 86篇 |
1989年 | 92篇 |
1988年 | 62篇 |
1987年 | 48篇 |
1986年 | 39篇 |
1985年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
《HPB : the official journal of the International Hepato Pancreato Biliary Association》2022,24(5):681-690
BackgroundThe American Joint Committee on Cancer (AJCC) made improvements for staging pancreatic neuroendocrine tumors (pNETs) in its 8th Edition; however, multicenter studies were not included.MethodsWe collected multicenter datasets (n = 1,086, between 2004 and 2018) to validate the value of AJCC 8 and other coexisting staging systems through univariate and multivariate analysis for well-differentiated (G1/G2) pNETs.ResultsCompared to other coexisting staging systems, AJCC 7 only included 12 (1.1%) patients with stage III tumors. Patients with European Neuroendocrine Tumor Society (ENETS) stage IIB disease had a higher risk of death than patients with stage IIIA (hazard ratio [HR]: 4.376 vs. 4.322). For the modified ENETS staging system, patients with stage IIB disease had a higher risk of death than patients with stage III (HR: 6.078 vs. 5.341). According to AJCC 8, the proportions of patients with stage I, II, III, and IV were 25.7%, 40.3%, 23.6%, and 10.4%, respectively. As the stage advanced, the median survival time decreased (NA, 144.7, 100.8, 72.0 months, respectively), and the risk of death increased (HR: II = 3.145, III = 5.925, and IV = 8.762).ConclusionThese findings suggest that AJCC 8 had a more reasonable proportional distribution and the risk of death was better correlated with disease stage. 相似文献
2.
《The journal of pain》2022,23(9):1604-1615
With the advent of platinum and taxane compounds used as single agents or in combination regimens, survival rates for some of the most common cancers have improved substantially. However, information on differences in the chemotherapy-induced peripheral neuropathy (CIPN) phenotype among single and combination regimens is limited. Study's purposes were to evaluate for differences in demographic and clinical characteristics; subjective and objective measures of CIPN; as well as the severity of common symptoms and quality of life among survivors who received platinum- (n = 95), taxane- (n = 200), or platinum and taxane-containing (n = 131) regimens. Patients completed self-report questionnaires (ie, duration of CIPN, pain intensity, pain qualities, pain interference) and underwent a physical examination that evaluated light touch, pain, and cold sensations and balance. For most of the subjective and objective measures of CIPN, as well as symptom severity and quality of life scores, no differences were found among the 3 chemotherapy groups. In all 3 chemotherapy treatment groups, CIPN was a painful, small fiber, and length dependent neuropathy. These findings support the hypothesis that CIPN induced by different classes of chemotherapy, as single agents or in combination, produce a similar CIPN phenotype which raises the possibility that CIPN induced by diverse chemotherapy protocols has the same underlying mechanism.PerspectiveIn this study, that compared patients who received only platinum, only taxane, or both platinum and taxane containing regimens, no differences were found among the 3 groups in the CIPN phenotype. Findings raise the possibility that CIPN induced by diverse chemotherapy protocols has the same underlying mechanism. 相似文献
3.
肺癌是我国最常见且死亡率最高的恶性肿瘤之一,随着表皮生长因子受体(EGFR)、间变性淋巴瘤激酶(ALK)及活性氧1(ROS1)等驱动基因及其相应分子靶向药物的出现,晚期非小细胞肺癌的治疗和预后发生了革命性变化。此外,一些少见新型驱动基因融合,包括神经调节蛋白1(NRG1)、神经营养酪氨酸受体激酶(NTRK)和转染重排因子(RET),正逐渐发展成为全身性治疗选择。然而,这些罕见新型融合驱动基因在NSCLC脑转移中的作用机制,以及优化控制和预防脑转移的意义人们所知甚少。因此,本文就近几年罕见驱动基因融合在NSCLC脑转移中的研究进行综述。 相似文献
4.
5.
6.
7.
8.
以华中科技大学同济医学院附属同济医院为例,探讨医院通过健全POCT管理体系,并借助信息平台改进POCT管理的经验,为其他医院POCT规范化管理提供参考。该医院通过搭建POCT管理平台,实现了设备标准化准入、人员资质统一授权、设备自动化质控和诊疗全流程闭环管理;基于信息平台的POCT管理改进,提升了医护人员的POCT认知度和操作水平,提高了医疗工作效率;实行诊疗全程风险管控,保障了医疗安全。 相似文献
9.
10.